TMCnet News
iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two posters at the Antibody Engineering & Therapeutics Conference 2022 [AE&T] in San Diego, California, December 4-8. The AE&T Conference features the latest science and research in antibody engineering, design, and selection to drive commercial advances in fields such as immuno-oncology. iBio will highlight applications of iBio's artificial intelligence-powered RubrYc Discovery Engine in the following posters:
About iBio, Inc. iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com. Investor Relations Media Relations
|